Novus Biologicals Announces New USP22 Antibody made using SDIX Genomic Antibodiesâ„¢

Novus Biologicals announced today a new USP22 antibody (catalog number NBP1-49644), a Golgi Apparatus marker and useful for the study of ubiquitin-dependent metabolic pathways. This USP22 antibody was made using SDIX Genomic Antibody TechnologyTM (GATTM). 

Deubiquitinating enzymes (DUBs) comprise a large group of proteases that cleave ubiquitin from proteins to regulate ubiquitin-dependent metabolic pathways. DUB proteins are responsible for ubiquitin recycling, ubiquitin precursor processing, protein ubiquitination proofreading, and inhibitory ubiquitin chain disassembly. Also known as deubiquitinating peptidases, deubiquitinating isopeptidases, deubiquitinases, ubiquitin proteases, ubiquitin hydrolyases or ubiquitin isopeptidases, DUBs can act as both positive and negative regulators of the ubiquitin system. Please visit our website for a complete list of all our ubiquitin proteasome pathway related products.

Ubiquitin carboxyl-terminal hydrolase 22 (USP22) is the DUB component of the transcription regulatory histone acetylation complex SAGA, which coactivates histones H2A and H2B by catalyzing their deubiquitination. Novus has recently released a new USP22 Antibody (NBP1-49644) for use in Western blot on human and mouse samples. USP-22 is also thought to be required for transcription, nuclear receptor-mediated transactivation and cell cycle progression, so the USP22 antibodies will serve as important tools for new research in a diverse set of areas.

SDIX GAT uses sophisticated bioinformatics and immunization strategies to produce high-quality antibodies that specifically bind to targeted regions of the protein in its naturally folded form. The ability of an antibody to recognize a protein’s naturally folded state enables its utility in high-value applications like sandwich immunoassay, ChIP, and flow cytometry.  Learn more about SDIX Genomic Antibodiesâ„¢ by reading the SDIX Genomic Antibodies FAQ or by downloading the SDIX Genomic  Antibodies White Paper.

About Novus Biologicals (

Novus Biologicals is a biotechnology company whose mission is to accelerate scientific discovery by developing and marketing unique products in the forefront of science.  Novus Biologicals provides primary antibodies, secondary antibodies, conjugated antibodies, proteins, peptides, isotype and loading controls, RNAi, lysates, stem cell lines and antibody labeling kits to the bioscience community.  All of Novus' products are 100% guaranteed to work in the species and applications listed on the datasheet.  By serving niche and emerging markets, Novus Biologicals has formed and will continue to form ongoing partnerships with leading researchers.

About SDIX (

SDIX is a biotechnology company with a core expertise at creating better antigens, better antibodies and better assays for the pharmaceutical, biotechnology and food safety markets. For over 20 years, SDIX has been a leading immuno-solutions Company, developing results-oriented and innovative antibody-based solutions that enable customers to meet high performance research, diagnostic and commercialization objectives.

In the life science market, SDIX’s technology and capabilities are being used to help discover disease mechanisms, facilitate development of new drugs, and provide antibodies and assays for the diagnosis of disease.  In the food safety market, SDIX continues to expand its footprint as an international supplier of rapid pathogen test technologies that enable more accurate and cost effective results.

This news release may contain forward-looking statements reflecting SDIX's current expectations. When used in this press release, words like “anticipate”, “could”, “enable”, “estimate”, “intend”, “expect”, “believe”, “potential”, “will”, “should”, “project”, “plan” and similar expressions as they relate to SDIX are intended to identify said forward-looking statements. Investors are cautioned that all forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those anticipated by SDIX at this time. Such risks and uncertainties include, without limitation, changes in demand for products, the application of our technologies to various uses, delays in product development, delays in market acceptance of new products, retention of customers and employees, adequate supply of raw materials, inability to obtain or delays in obtaining fourth party or required government approvals, the ability to meet increased market demand, competition, protection of intellectual property, non-infringement of intellectual property, seasonality, and other factors more fully described in SDIX's public filings with the U.S. Securities and Exchange Commission.


Release Date: 
Tuesday, April 26, 2011 - 06:00